Immix Biopharma, Inc.

NASDAQ: IMMX · Healthcare · Biotechnology

PublicHQ Los Angeles, CA · Los AngelesCIK 0001873835Reports USD

#544 of 1,418 Healthcare companies by revenue

EA Score

49D

FH 59DQ 35GM —SS 43

v0.1 · 55/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$29.4M

Employees

as of 2026-08-11

Market cap

$551.1M

as of 2026-08-11

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$20.0M$20.0M2023

Net income-$29.4M-$29.4M2025

Operating income-$30.0M-$30.0M2025

Total assets$104.8M$104.8M2025

Liabilities$11.0M$11.0M2025

Equity$93.8M$93.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Immix Biopharma, Inc.’s revenue?

Immix Biopharma, Inc. booked $20.0M in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -147.2% net margin.

Peers · Healthcare

Evofem Biosciences, Inc.42D Acutus Medical, Inc.——Nutrition Management Services Company——Spectral AI, Inc.39D Carisma Therapeutics, Inc.——Sonoma Pharmaceuticals, Inc.60C

Neighbors

Los Angeles →

The Walt Disney Company$94.4B72B Public Storage$4.8B80B+Southern California Gas Company PFD SER A 6%——Ares Management Corporation$5.6B68B Live Nation Entertainment, Inc.$25.2B76B+Rocket Lab USA, Inc.$601.8M50D

Key facts

CEOIlya Rachman

SectorHealthcare

IndustryBiotechnology

HeadquartersLos Angeles, CA

ExchangeNASDAQ: IMMX

Employees21

IPO date2021-12-16

Latest filings

10-Q2026-08-07 8-K2026-07-20 8-K2026-05-29 8-K2026-05-21 8-K2026-05-21 10-Q2026-05-07 DEF 14A2026-04-06 8-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.